MAIA Biotechnology Reports Extended Survival in NSCLC Trial
Event summary
- MAIA Biotechnology reported overall survival exceeding two years for eight patients in its ongoing Phase 2 THIO-101 clinical trial for non-small cell lung cancer (NSCLC).
- The trial evaluated ateganosine sequenced with cemiplimab in heavily pre-treated patients who had failed previous checkpoint inhibitor treatments.
- Five of the eight patients have ongoing survival follow-up, with one patient in third-line therapy surviving 33 months.
- The Phase 2 trial treated 79 patients in Parts A and B, with Part C expansion currently enrolling up to 48 participants in Asia and Europe.
The big picture
MAIA Biotechnology's Phase 2 trial results highlight the potential of ateganosine as a breakthrough therapeutic option for NSCLC, targeting a heavily pre-treated patient population. The extended survival data positions ateganosine as a potential disruptor in the immunotherapy market, which is dominated by checkpoint inhibitors. The ongoing Phase 3 trial and Part C expansion will be critical in validating ateganosine's long-term efficacy and safety profile.
What we're watching
- Clinical Efficacy
- Whether ateganosine's telomere-targeting mechanism can sustain long-term survival benefits in advanced NSCLC patients.
- Regulatory Pathway
- The pace at which MAIA can advance ateganosine through Phase 3 trials and secure regulatory approval.
- Market Potential
- How MAIA positions ateganosine in the $50B+ global immunotherapy market against existing checkpoint inhibitors.
Related topics